IGHE and ovarian carcinoma: We previously reported the in vivo efficacy of recombinant chimeric (mouse/human) antibody, hMOv18 IgE, specific for the human tumour‐associated antigen folate receptor α (FRα), overexpressed in solid tumours including ovarian carcinomas.